An editorial highlights that the issue of how best to approach this patient population in contemporary practice remains controversial because not all studies have identified benefit from immediate treatment and patients are increasingly worried about side effects of treatment. It highlights that a balanced and nuanced approach is required to treating men with biochemical recurrence after receipt of surgery or radiation for early-stage prostate cancer. New technologies and contemporary information will further refine approaches, which better balance survival against the morbidity of treatment.